Keros Therapeutics (KROS) Earnings Date, Estimates & Call Transcripts $11.38 -0.55 (-4.61%) Closing price 03/7/2025 04:00 PM EasternExtended Trading$11.60 +0.22 (+1.93%) As of 03/7/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Keros Therapeutics Latest Earnings SummaryUpcoming Q1 Earnings DateMay. 14Before Market OpensEstimatedActual EPS (Feb. 26) -$1.14 Beat By $0.22 Consensus EPS (Feb. 26) -$1.36 Keros Therapeutics posted Q4 2024 earnings on February 26, 2025, reporting an EPS of -$1.14, which beat the consensus estimate of -$1.36 by $0.22. Quarterly revenue was reported to be $3.04 million, below analysts' expectations of $37.32 million. With a trailing EPS of -$5.01, Keros Therapeutics' earnings are expected to decrease next year, from ($4.74) to ($4.87) per share. KROS Upcoming EarningsKeros Therapeutics' next earnings date is estimated for Wednesday, May 14, 2025, based off prior year's reporting schedules. Get Keros Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataKROS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KROS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Keros Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$1.40-$1.23-$1.30Q2 20254-$1.39-$1.02-$1.21Q3 20254-$1.37-$0.66-$1.03Q4 20254-$1.41-$0.58-$0.99FY 202515-$5.57-$3.49-$4.53Q1 20261-$0.61-$0.61-$0.61Q2 20261-$0.62-$0.62-$0.62Q3 20261-$0.62-$0.62-$0.62Q4 20261-$0.62-$0.62-$0.62FY 20264($2.47)($2.47)($2.47) Remove Ads Keros Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/14/2025(Estimated)-------2/26/2025Q4 2024-$1.36-$1.14+$0.22-$1.14$37.32M$3.04M11/6/2024Q3 2024-$1.28-$1.41 -$0.13-$1.41-$0.39M8/7/2024Q2 2024-$1.23-$1.25 -$0.02-$1.25-$0.04M5/8/2024Q1 2024-$1.33-$1.21+$0.12-$1.21-$0.08M3/1/2024Q4 2023-$1.37-$1.34+$0.03-$1.34-$0.14M11/6/2023Q3 2023-$1.35-$1.33+$0.02-$1.33-$0.01M8/7/2023Q2 2023-$1.34-$1.27+$0.07-$1.27$0.22M-5/4/2023Q1 2023-$1.14-$1.26 -$0.12-$1.26$0.22M- Keros Therapeutics Earnings - Frequently Asked Questions When is Keros Therapeutics's earnings date? Keros Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 14th, 2025 based off last year's report dates. Learn more on KROS's earnings history. Did Keros Therapeutics beat their earnings estimates last quarter? In the previous quarter, Keros Therapeutics (NASDAQ:KROS) reported ($1.14) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.36) by $0.22. Learn more on analysts' earnings estimate vs. KROS's actual earnings. How much revenue does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded annual revenue of $3.55 million. How much profit does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded net income of -$152.99 million. KROS has generated -$5.01 earnings per share over the last four quarters. What is Keros Therapeutics's EPS forecast for next year? Keros Therapeutics's earnings are expected to decrease from ($4.74) per share to ($4.87) per share in the next year. More Earnings Resources from MarketBeat Related Companies TVTX Earnings GLPG Earnings IDYA Earnings JANX Earnings TARS Earnings IRON Earnings SDGR Earnings KNSA Earnings WVE Earnings ARQT Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance? Remove Ads This page (NASDAQ:KROS) was last updated on 3/10/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAI Shock Coming on March 18? Prepare NowIf you’re worried about all the recent volatility in the market… Or if you have any money in AI stocks… ...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KROS Stock Alerts